LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 14 of 15: Mean cell count and mean normalized growth rate inhibition values across all replicates. - Dataset (ID:20251)

Filter results: >>>>
Cell Small Molecule Small Mol Concentration Small Mol Conc Unit LJP Library Plate Mean Relative Cell Count Standard Error of the Mean for Relative Cell Count Mean Normalized Growth Rate Inhibition Value Standard Error of the Mean for Normalized Growth Rate Inhibition Value
SK-BR-3 Erlotinib
0.04
uM
LJP5
0.8398 0.0212 0.7558 0.0445
SK-BR-3 Erlotinib
0.12
uM
LJP5
0.9209 0.0240 0.8848 0.0347
SK-BR-3 Erlotinib
0.37
uM
LJP5
0.9606 0.0322 0.9456 0.0493
SK-BR-3 Erlotinib
1.11
uM
LJP5
0.9398 0.0278 0.9106 0.0418
SK-BR-3 Erlotinib
3.33
uM
LJP5
0.9072 0.0339 0.8676 0.0461
SK-BR-3 Erlotinib
10
uM
LJP5
0.4802 0.0088 0.1648 0.0670
SK-BR-3 Gefitinib
0.04
uM
LJP6
0.9452 0.0141 0.9089 0.0316
SK-BR-3 Gefitinib
0.12
uM
LJP6
0.8377 0.0108 0.7403 0.0363
SK-BR-3 Gefitinib
0.37
uM
LJP6
0.7304 0.0167 0.5669 0.0441
SK-BR-3 Gefitinib
1.11
uM
LJP6
0.6411 0.0164 0.4181 0.0571
SK-BR-3 Gefitinib
3.33
uM
LJP6
0.5973 0.0209 0.3424 0.0690
SK-BR-3 Gefitinib
10
uM
LJP6
0.4319 0.0147 0.0480 0.0840
SK-BR-3 Nilotinib
0.04
uM
LJP5
1.0699 0.0309 1.1000 0.0427
SK-BR-3 Nilotinib
0.12
uM
LJP5
1.0793 0.0197 1.1127 0.0247
SK-BR-3 Nilotinib
0.37
uM
LJP5
1.1077 0.0150 1.1544 0.0165
SK-BR-3 Nilotinib
1.11
uM
LJP5
1.0825 0.0283 1.1149 0.0300
SK-BR-3 Nilotinib
3.33
uM
LJP5
1.0600 0.0318 1.0830 0.0390
SK-BR-3 Nilotinib
10
uM
LJP5
0.5039 0.0138 0.2077 0.0559
SK-BR-3 JNK-9L
0.04
uM
LJP6
0.7775 0.0332 0.6485 0.0552
SK-BR-3 JNK-9L
0.12
uM
LJP6
0.8277 0.0478 0.7352 0.0718
SK-BR-3 JNK-9L
0.37
uM
LJP6
0.7744 0.0539 0.6452 0.0865
SK-BR-3 JNK-9L
1.11
uM
LJP6
0.4856 0.0301 0.1500 0.0473
SK-BR-3 JNK-9L
3.33
uM
LJP6
0.3383 0.0304 -0.1290 0.0513
SK-BR-3 JNK-9L
10
uM
LJP6
0.3046 0.0135 -0.1959 0.0754
SK-BR-3 PD0325901
0.04
uM
LJP5
0.9312 0.0137 0.8974 0.0211